The Medicines Company
) recently presented full results on its phase III candidate,
Cangrelor, from the phase III double-blind, CHAMPION PHOENIX
study. Cangrelor was compared to oral clopidogrel in patients
undergoing percutaneous coronary intervention (PCI) in the study.
We note that clopidogrel is marketed by
Bristol-Myers Squibb Company / Sanofi
) under the brand name Plavix.
Results showed that cangrelor lowered the chances of the
occurrence of ischemic events by 22% compared to clopidogrel in
48 hours. The Medicines Company also said that the chances of the
occurrence of stent thrombosis, the secondary endpoint, was
lowered by 38% in the cangrelor arm.
The findings were consistent across different groups and
sub-groups of patients. The safety findings revealed that adverse
events in both treatment groups were found to be similar.
However, cases of transient dyspnea were more in the cangrelor
The Medicines Company anticipates filing a new drug
application (NDA) to the US Food and Drug Administration (FDA) in
the second quarter of this year. The Medicines Company also
expects to file for EU approval in the second half of 2013.
We remind investors that The Medicines Company is developing
for the prevention of platelet activation and aggregation that
leads to thrombosis in the acute care setting, including patients
We are positive on The Medicines Company's progress with its
Cangrelor is quick in action and instantly reversible. The
candidate is thus expected to play an important role in patients
undergoing PCI and those who need to discontinue oral P2Y12
inhibitors ahead of surgery.
The Medicines Company carries a Zacks Rank #3 (Hold). However,
other pharma stocks like
Avanir Pharmaceuticals, Inc
) carry a Zacks Rank #2 (Buy).
AVANIR PHARM (AVNR): Free Stock Analysis
BRISTOL-MYERS (BMY): Free Stock Analysis
MEDICINES CO (MDCO): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.